What’s new

• Board approved rights issue of up to ₹50 crore, matching ~91% of company's ₹55 crore market cap.
• Authorised capital raised by ₹45 crore to ₹65 crore; intermediaries appointed including monitoring agency.
• Two independent directors resigned: Dinesh Chander Notiyal and Avani Savjibhai Godhaniya.

Why it matters

For a company with trailing ROE of 1.6% and zero quarterly sales, a rights issue equal to almost the entire market cap will flood the stock with shares. The simultaneous exit of two independent directors adds governance concerns. Existing holders face severe dilution; the stock's recent insider selling suggests limited confidence even before this move.

What we’re watching

• Rights issue price and entitlement ratio (determines actual dilution).
• Whether the company discloses a concrete use of proceeds.
• Any further board changes or auditor resignations.

The full read

Bacil Pharma's market cap is ₹55 crore. The company, which reported zero sales last quarter, just approved a rights issue of ₹50 crore effectively equal to its entire equity value. To accommodate the new shares, it hiked authorised capital from ₹20 crore to ₹65 crore, appointed Acuite Ratings as monitoring agency, and lost two independent directors in the same board meeting. The rights issue was a known possibility; the exact quantum and the simultaneous governance churn are new. Existing holders, already seeing insider stake sales in the past weeks (Niraj Shah sold 2.75% just last week), now face massive dilution in a stock with 36.7x trailing P/E and 1.6% ROE. The question is not whether Bacil needs money; it is what that money buys that a ₹55 crore market cap could not.

Primary source: BSE · NSE

What’s new

• Niraj Shah bought 925,000 shares (6.44% stake) via open market from June 22-24.
• Bacil Pharma has zero operating revenue and a market cap of just ₹57 crore.
• The purchase follows recent stake sales by two other non-promoter shareholders.

Why it matters

A new substantial holder entering a nano-cap with no revenue is a bet on a turnaround or a future fundraise. The board is set to discuss fundraising on June 26, and Shah's entry just days before may signal confidence in that plan.

What we’re watching

• Outcome of the board meeting on June 26 regarding fundraising.
• Whether Shah increases his stake further or other holders follow suit.
• Any change in Bacil's revenue trajectory in coming quarters.

The full read

The timing is hard to ignore. Niraj Rajnikant Shah bought 925,000 shares, a 6.44% stake, over three trading days just before Bacil Pharma's board meets on June 26 to discuss fundraising. The nano-cap with a ₹57 crore market cap reported zero operating revenue for FY26. Two other non-promoter shareholders had reduced their stakes earlier in June. Shah's entry into a zero-revenue company is a bet that the board's fundraise can change the trajectory. It is a bet without revenue cover, only a board decision.

Primary source: BSE · NSE

What’s new

• Manubhai Amrutlal Shah sold 394,893 shares (2.75% equity) on June 23-24, cutting his holding from 12.77% to 10.02%.
• This follows a 5.57% sale earlier in June, making his total June disposal over 8%.
• Another substantial shareholder, Patel, had sold a 7.10% stake just days before.

Why it matters

For a company with zero operating revenue and a market cap of just ₹60 crore, the rapid exit of two large non-promoter holders in June signals a clear loss of confidence. Shah's stake now hovers just above the 10% substantial-holder threshold, inviting further sell-downs. The board's upcoming fundraising meet on June 26 raises the question of who will back a shell.

What we’re watching

• Whether Shah cuts further below the 10% threshold in coming sessions.
• The outcome of the June 26 board meeting on fundraising options.
• Any regulatory triggers if substantial holdings drop further.

The full read

Bacil Pharma has lost another large non-promoter holder. Manubhai Amrutlal Shah sold 2.75% of the company on June 23-24, his second batch in June, taking his monthly total to over 8% and cutting his stake to 10.02%. This follows news just yesterday that another substantial shareholder, Patel, dumped 7.10% over two days. For a nano-cap reporting zero operating revenue and with a market cap of just ₹60 crore, the pace of insider selling is stark. A board meeting on June 26 to discuss fundraising sounds like an ask for capital at a company no one wants to own. With Shah now a whisker above the 10% threshold, the next move is likely more sales, not fewer.

Primary source: BSE · NSE

What’s new

• Nikita Hiren Patel sold 7.10% equity on June 22-23, reducing her stake to 10.07%
• This is her second sale this month: she sold 2.27% earlier in June
• The sales come amid zero operating revenue and a ₹60 cr market cap

Why it matters

A substantial shareholder exiting nearly half her stake in two transactions within weeks signals waning conviction in a company with no revenue. For a ₹60-cr nano-cap, this volume of selling can skew the stock price and raise questions about the remaining holders' commitment.

What we’re watching

• Whether Patel sells further; she remains a 10% holder and could cross below the material threshold
• Bacil's board meets June 26 to discuss fundraising — any clarity on use of funds could matter
• Market reaction: another large holder's exit after a 5.57% sale on June 13

The full read

Nikita Hiren Patel, a substantial non-promoter shareholder in Bacil Pharma, has sold 7.10% of the company in two days, June 22–23. That follows an earlier 2.27% sale this month. Her stake now stands at 10.07%, down from 17.17%. The ₹60-cr nano-cap has zero operating revenue and net profit of just ₹1 crore from other income in the March 2026 quarter. The selling comes after a 5.57% exit by another large holder on June 13 and a week after promoters proposed an R&D arm, a plan that lacks detail for a company with no sales. Patel's rapid exits look less like rebalancing and more like an exit. The board meets June 26 to discuss fundraising; what that money would be used for is the open question. Until then, every large sale at Bacil is a signal, not a noise.

Primary source: BSE · NSE

What’s new

• Board meeting set for June 26 to evaluate fundraising proposals.
• Options include preferential issue, rights issue, or convertible securities.
• Trading window closed until 48 hours after outcome.

Why it matters

For a company with zero revenue and a ₹60 cr market cap, any fund raise could transform its balance sheet. But this is a preliminary notice. No issue size, pricing, or dilution details. The actual impact remains speculative until concrete terms emerge.

What we’re watching

• Disclosure of issue size, price, and dilution in the board outcome.
• Any promoter participation or follow-on stake changes.
• Progress on the R&D arm proposed earlier amid zero operational revenue.

The full read

Bacil Pharma, a nano-cap with zero operating revenue and a ₹60 cr market cap, has scheduled a board meeting for June 26 to discuss fundraising. Options include a preferential issue, rights issue, or convertible securities. No specifics on size, price, or dilution have been released. This is a preliminary notice, not a decision. The company has been in the spotlight recently: a non-promoter sold 5.57% in a single day, and an R&D arm was proposed without financial details. Given the absence of revenue, any equity raise would be a defining event, but today's filing is just a procedural step. The open question is whether management will share concrete terms or if this remains exploratory.

Primary source: BSE · NSE

What’s new

• Bacil Pharma proposes to incorporate Bacil Research & Development Private Limited as a wholly-owned subsidiary.
• The subsidiary will focus on R&D and allied operations, subject to statutory approvals.
• No financial commitment, investment amount, or revenue projections disclosed.

Why it matters

For a company with zero operating revenue, an R&D subsidiary signals a strategic turn, but the filing is all intent and no detail. Without a disclosed investment or timeline, this remains a placeholder. The market cap of ₹57 cr means even a small cash outlay would matter, yet Bacil hasn't said how much it plans to spend.

What we’re watching

• Whether Bacil discloses the investment amount or commits capital to the subsidiary.
• Progress on regulatory approvals from the RoC and other authorities.
• If this is followed by a fundraise, given the company's opaque cash needs.

The full read

Bacil Pharma wants to start an R&D subsidiary. That's the news. But for a company that reported ₹0 crore in sales last quarter and a ₹1 crore net profit that masks operating losses, the filing is an intention, not a plan. Bacil Research & Development Private Limited, a wholly-owned arm, will focus on R&D subject to approvals. What's missing: any investment figure, any timeline, any revenue target. The market cap of ₹57 cr means even a small capital commitment would be material, yet the company has said nothing about how much it will spend. Promoter exits in June 2026, with 5.57% and 2.27% stake sales, add to caution. The idea is interesting. The numbers aren't there yet.

Primary source: BSE · NSE

What’s new

• Manubhai Shah sold 5.57% of Bacil Pharma via open market on June 10.
• His stake dropped from 18.34% to 12.77%.
• Follows a 2.27% sale by another non-promoter just days earlier.

Why it matters

For a company with zero operating revenue and a ₹63 crore market cap, two substantial open-market exits in a week signal that the largest shareholders are losing patience. The stock may face pressure as retail holders question the thesis.

What we’re watching

• Whether more non-promoter holders follow suit.
• Any update on Bacil Pharma's business plans or lack thereof.
• Market reaction in the coming sessions.

The full read

Manubhai Amrutlal Shah sold 5.57% of Bacil Pharma in a single day, cutting his stake from 18.34% to 12.77%. That makes two substantial open-market exits in a week. Nikita Patel sold 2.27% days earlier. Between them, Bacil Pharma's largest non-promoter holders have cut their collective exposure by almost 8% of the company's equity. For a nano-cap with ₹63 crore market cap and zero operating revenue. That is a flashing signal. The company's latest quarter reported sales of ₹0 crore and a tiny net profit of ₹1 crore, likely from non-operating items. The pattern is clear: the shareholders who know the business best are leaving. Retail investors who bought the story of a pharma turnaround are now holding a company without revenue and with its biggest backers heading for the exits.

Primary source: BSE · NSE

What’s new

• Nikita Hiren Patel sold 326,104 shares (2.27%) on June 8-9 via open market.
• Her holding fell from 19.44% to 17.17% of the company's equity.
• The transaction was disclosed to the BSE under SEBI's substantial acquisition rules.

Why it matters

Bacil Pharma reports zero operating revenue. Its ₹68 crore market cap rests on other income and speculation. When the single largest outside investor trims a material stake, it is a direct signal about conviction. The filing gives no reason for the sale.

What we’re watching

• Whether Patel continues to offload her remaining 17.17% stake.
• Any explanatory statement from the company or the seller.
• The stock's price and volume reaction in subsequent sessions.

The full read

Nikita Patel, Bacil Pharma's largest non-promoter shareholder, sold 2.27% of the company's equity. The open-market transactions on June 8 and 9 trimmed her stake from 19.44% to 17.17%. Bacil Pharma is a nano-cap with a market capitalisation of about ₹68 crore and ₹0 in operating revenue. The company's latest quarter showed ₹0 in sales. For a business with no revenue, the stock price is a speculative bet. A significant stake reduction by the biggest outside investor is a direct signal about their conviction. The filing provides no reason for the sale. Against a backdrop of zero revenue, that silence is the most concrete detail.

Primary source: BSE · NSE

What’s new

• Bacil Pharma recorded zero revenue from operations for the full fiscal year.
• Total other income stood at ₹123.52 lakhs, resulting in a ₹155.55 lakhs profit after tax.
• Fair value adjustments caused a total loss of ₹61.88 lakhs.

Why it matters

The company exists as an entity without underlying commercial activity. While the auditor issued an unmodified opinion, the financial health depends on accounting items rather than actual business performance.

What we’re watching

• Any sign of business revival or asset liquidation.
• Future auditor comments regarding the company's status.
• Persistence of fair value volatility in upcoming quarters.

The full read

Bacil Pharma stays locked in a non-operational state. The company ended the year with ₹0 in revenue from operations, relying entirely on ₹123.52 lakhs of other income to generate a reported profit after tax of ₹155.55 lakhs. Once fair value losses were accounted for, the bottom line shifted into a total loss of ₹61.88 lakhs. This is a routine annual disclosure. The auditor provided an unmodified opinion, a step up from previous disclaimers, but the core reality remains unchanged. The company holds no commercial momentum. It is a paper entity that produced no sales for the duration of the fiscal year. Nothing in these results breaks from the trends seen in quarterly updates.

Primary source: BSE · NSE

What’s new

• Bacil Pharma posted zero operating revenue for FY26.
• The firm recorded ₹123.52 lakhs in income from investments.
• Auditors issued an unmodified opinion with an emphasis of matter.

Why it matters

The annual report confirms the firm has no commercial business. It relies entirely on asset returns to survive. The results offer no evidence of a path forward.

What we’re watching

• Any potential pivot in business strategy.
• Updates regarding the company's long-standing governance issues.
• Changes to the investment portfolio.

The full read

Bacil Pharma’s FY26 results confirm the firm is an inactive shell. The company reported zero operating revenue for the year, relying entirely on ₹123.52 lakhs in other income derived from its investments. After accounting for fair value losses on financial assets, the company booked a total loss of ₹61.88 lakhs.

Auditors provided an unmodified opinion, though they added an emphasis of matter paragraph. These figures surprise no one. They align with previous quarterly disclosures detailing the company’s lack of commercial operations. This filing is a routine regulatory requirement that signals the firm’s continued stagnation. With no pending litigation reported, the business remains stuck in a holding pattern.

Nothing changed.

Primary source: BSE · NSE